Recent Dyslipidemia Guidelines Emphasize Early Intervention and Comprehensive Risk Assessment

The American Heart Association (AHA), American College of Cardiology (ACC), and the Multisociety have jointly released updated guidelines for the management of dyslipidemia, reflecting significant advancements in testing, tools, and treatments over the past seven years. The 2026 guidelines emphasize early detection and treatment, personalized risk assessment, and a comprehensive approach to cardiovascular (CV) health.

Key Recommendations from the 2026 Guidelines

Test and Treat Early

Recognizing the rising rates of obesity, diabetes, and myocardial infarction (MI) in young adults, the guidelines recommend initiating lipid screening at ages 9 to 11 years, then again at ages 19 to 21 years, and subsequently at least every five years. Early health behavior counseling is as well encouraged for youth. Lipid-lowering therapy should be considered for young adults with persistent LDL cholesterol of at least 160 mg/dL, a strong family history of atherosclerotic cardiovascular disease (ASCVD), or a 10-year ASCVD risk of 10% or greater.

Calculate, Personalize, Reclassify, Reassess (CPR)

A systematic approach to guide lipid-lowering therapy is outlined using the “CPR” method: first Calculate 10-year ASCVD risk using the PREVENT equation, then Personalize the estimated risk considering patient-specific risk enhancers, Reclassify with coronary artery calcium (CAC) scoring when the decision remains uncertain, and finally Reassess treatment recommendations.

PREVENT Equations and Risk Thresholds

The PREVENT equations estimate risk for overall CVD, ASCVD, and heart failure. For dyslipidemia management, the PREVENT-ASCVD estimate should be used. Lipid-lowering therapy can be considered for primary prevention in adults with an estimated 10-year ASCVD risk of 3% to 5% (borderline risk) with risk enhancers, and is recommended at 5% to 10% risk (intermediate risk).

LDL and Non-HDL Cholesterol Goals

The guidelines reinstate specific LDL and non-HDL cholesterol goals. Target LDL levels are less than 55 mg/dL for highly high risk, less than 70 mg/dL for high risk, and less than 100 mg/dL for borderline-intermediate risk. Corresponding non-HDL goals are less than 85 mg/dL, less than 100 mg/dL, and less than 130 mg/dL, respectively – 30 points higher than LDL goals.

Apolipoprotein B

Once LDL and non-HDL levels are at or near goal, particularly in individuals with high triglycerides or diabetes, apolipoprotein B (ApoB) measurement can be considered to guide further treatment intensification. Target ApoB levels are less than 55 mg/dL for very high risk, less than 70 mg/dL for high risk, and less than 90 mg/dL for borderline-intermediate risk patients.

Lipoprotein(a)

Lipoprotein(a) [Lp(a)] is a genetically determined, highly atherogenic lipoprotein. Checking Lp(a) at least once in a patient’s lifetime is recommended to support intensified preventive efforts. Levels of at least 125 nmol/L are considered a risk enhancer, associated with a 1.4-fold increased ASCVD risk, while levels of at least 250 nmol/L are associated with more than a twofold increased risk.

Coronary Artery Calcium (CAC) Scoring

CAC scoring is a safe, affordable, and validated marker of atherosclerotic risk. It can be used to reclassify patients for whom lipid-lowering decision-making is uncertain, considering both absolute CAC and the corresponding standardized percentile.

Primary and Secondary Prevention

Adults aged 40 to 75 years with diabetes, chronic kidney disease (stages 3-4), or HIV should be treated with lipid-lowering therapy regardless of LDL level. Lipid lowering remains beneficial in adults with dyslipidemia older than 75 years. Lifestyle optimization and shared decision-making are key to supporting healthy CV aging.

For secondary prevention, an LDL level of less than 55 mg/dL is recommended for most patients, especially those with a history of two or more major ASCVD events or one major ASCVD event and two high-risk conditions. A stepwise approach to treatment is recommended, starting with maximally tolerated statins, then adding ezetimibe, bempedoic acid, and/or a PCSK9 inhibitor, and finally considering inclisiran for further LDL lowering.

Managing Hypertriglyceridemia

Triglyceride levels of at least 150 mg/dL are associated with increased ASCVD risk and are responsive to lifestyle intervention. Statins remain the foundation of pharmacotherapy for persistently elevated triglycerides. For more substantial triglyceride lowering, fenofibrate and icosapent ethyl should be considered. Apolipoprotein C3 inhibitors have a role in familial chylomicronemia syndrome.

Implementing the Guidelines

With an aging population and the ongoing obesity epidemic, implementing these recommendations, detailed in the 2026 ACC/AHA/Multisociety Dyslipidemia Guideline, will be crucial to improving heart health across all populations and life stages.

Source: Blumenthal RS, et al. Circulation. 2026; doi:10.1161/CIR.0000000000001423.

Disclosure: Blumenthal and Martin were writing committee members for the 2026 Guideline on the Management of Dyslipidemia. The authors report no other relevant financial disclosures.